Every 10-Q that KORU Medical Systems, Inc. (KRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRMD filings page.
KORU Medical Systems reported strong top-line growth for the quarter ended June 30, 2026. Net revenues rose to $12.0 million, up 18.2% year over year, led by domestic core growth of 12.4% and international core growth of 59.1%, partly offset by a 35.0% decline in pharma services and clinical trials revenue.
Gross profit increased to $7.8 million with gross margin improving to 65.1% from 63.5%, while operating expenses grew 6.3% to $7.2 million. The company generated quarterly net income of $252,449, compared with a net loss in the prior-year quarter. For the first six months, net revenues were $23.8 million, up 20.1%, and the net loss narrowed to $554,629.
Cash and cash equivalents were $8.3 million at June 30, 2026, with net cash provided by operating activities of $230,776. KORU also has an undrawn $5.0 million revolving credit facility and a $5.0 million term loan, both amended in March 2026 to extend maturities and reduce interest-rate floors, and expects available liquidity to fund requirements for at least the next twelve months.
KORU Medical Systems, Inc. reported first-quarter 2026 net revenues of $11.8 million, up 22.1% from $9.6 million a year earlier, driven by growth across domestic, international, and pharma services businesses. Domestic core revenue rose 11.7%, international core grew 35.2%, and pharma services and clinical trials increased 166.0%.
Gross profit increased to $7.2 million, although gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Operating expenses rose 11.0% to $8.1 million, mainly from higher legal and compensation costs. Net loss narrowed to $0.8 million, or $0.02 per share, compared with a $1.2 million loss, or $0.03 per share, in the prior-year quarter.
The company ended the quarter with $8.8 million in cash and cash equivalents and $4.5 million of inventory, and generated essentially break-even operating cash flow. KORU amended its $10 million credit facility, extending maturities, lowering the interest rate floor to 5.50%, and lengthening the interest-only period on the term loan. The company expects existing cash, operations, and available credit to fund its needs for at least the next twelve months.
KORU Medical Systems (KRMD) reported Q3 2025 results with net revenues of $10.4 million, up 27.2% year over year. Core revenue reached $9.8 million (up 29.7%), driven by international core growth of 229.6%, while domestic core declined 5.0% due to ordering shifts and inventory reductions at a U.S. distributor.
Gross profit was $6.3 million, up 20.8%, with gross margin of 60.2% versus 63.4% a year ago, reflecting higher manufacturing costs, geographic mix, and tariff charges. Operating expenses were $7.1 million, modestly higher than last year. Net loss narrowed to $0.8 million from $1.6 million.
For the nine months, revenue was $30.2 million (up 21.9%) with a net loss of $2.2 million versus $4.5 million last year. Cash and cash equivalents were $8.5 million as of September 30, 2025, and there were no outstanding borrowings under the $5 million revolver or $5 million term facility. Management noted tariff-related charges of $0.1 million in Q3 and expects an annualized gross margin impact of less than 100 basis points.